Cipla Limited has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to commercialize clobetasol propionate ophthalmic suspension, 0.05% across 11 countries. This landmark deal will bring an innovative treatment for post-operative inflammation and pain following ocular surgery to key markets, including India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.
APP13007 is a USFDA-approved, patent-protected ophthalmic product designed to treat inflammation and pain following ocular surgery. Its twice-daily dosing regimen for 14 days without the need for tapering offers patients rapid and sustained relief, marking a significant advancement in ophthalmic care. This innovation strengthens Cipla’s commitment to enhancing post-operative eye care through cutting-edge solutions.
Achin Gupta, Global Chief Operating Officer of Cipla, emphasized the significance of the deal: “The partnership with Formosa Pharmaceuticals marks a significant milestone for Cipla, as it is our first multi-regional licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio. We look forward to leveraging Cipla’s strong commercial presence to make a meaningful impact in post-operative eye care.”
Cipla’s ophthalmology division continues to focus on developing treatments for conditions like glaucoma, dry eye disease, ocular infections, and retinal disorders. The strategic agreement with Formosa Pharmaceuticals involves upfront payments, royalty milestones, and additional value-driven considerations, reinforcing Cipla’s dedication to pioneering advancements in the global ophthalmic market.
